# semaglutide

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/semaglutide-company
Canonical HTML page: https://getbiobrief.com/entity/semaglutide-company

## Timeline

- **2026-09**: European Respiratory Society presentation — Professor Chloe Bloom presents a real-world UK electronic medical record analysis linking GLP-1 receptor agonists, particularly semaglutide, to fewer asthma attacks and COPD flare-ups.

## Recent coverage (1 stories)

### Semaglutide real-world data show 40% fewer asthma attacks in ERS study
2026-09-10 18:59:25 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Biopharma teams now have a strong observational signal that semaglutide could address asthma and COPD exacerbations, but a new indication will require prospective randomized trials. The findings may shape GLP-1 lifecycle strategies and respiratory pipeline investment.
Full story: https://getbiobrief.com/story/semaglutide-real-world-data-40-percent-asthma-copd-ers

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.